A Case of Psoriasiform Dermatitis Followed by Tumor Necrosis Factor Inhibitor Treated with Phototherapy.
10.4078/jrd.2013.20.4.270
- Author:
Gyun Seop LIM
1
;
Hyung Nam KIM
;
Bo Bae KIM
;
Dong Hyun KIM
;
Yun Sung KIM
;
Hyun Sook KIM
Author Information
1. Department of Internal Medicine, The Chosun University College of Medicine, Gwangju, Korea.
- Publication Type:Case Report
- Keywords:
Phototherapy;
Psoriasiform dermatitis;
TNF-alpha antagonist;
Rheumatoid arthritis
- MeSH:
Antibodies, Monoclonal, Humanized;
Arthritis, Rheumatoid;
Autoimmune Diseases;
Biopsy;
Dermatitis;
Dermatitis, Seborrheic;
Exanthema;
Extremities;
Female;
Head;
Humans;
Middle Aged;
Phototherapy;
Skin;
Tumor Necrosis Factor-alpha;
Urticaria;
Adalimumab
- From:Journal of Rheumatic Diseases
2013;20(4):270-274
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Although tumor necrosis factor (TNF)-alpha antagonist is a successful treatment modality for various autoimmune diseases, including rheumatoid arthritis (RA), ankylosing spondylitis and psoriatic arthritis, many adverse effects have been reported. Cutaneous adverse reactions of TNF-alpha antagonist include skin rash, urticaria, lupus like rash, seborrheic dermatitis and different kinds of psoriasiform dermatitis. We report a case of psoriasiform dermatitis during TNF-alpha antagonist treatment in a 50-year-old woman with RA. The patient has been treated with adalimumab. After 2 months, she developed pruritic erythematous eruption and desquamative lesions on the head and limbs, which were defined as psoriasiform change by a skin biopsy. These skin lesions are successfully treated with combination therapy, including cessation of adalimumab, corticosteroid and phototherapy.
